CAMBRIDGE, UNITED KINGDOM – Optibrium™, a developer of software for drug discovery, today announced a collaboration with InfoChem GmbH, a leader in cheminformatics. The collaboration provides StarDrop™ users with easy access to ICSYNTH light, an entry-level version of InfoChem’s computer-aided synthesis design (CASD) software to generate synthesis pathways for a target molecule. By stimulating new and […]

Big Data project will create comprehensive database of chemistry and bioactivity related content to help increase the visibility, reusability and actionability of existing information New York Elsevier, the information analytics business specializing in science and health, announced today that Lundbeck, the global pharmaceutical company specializing in brain diseases has selected Elsevier’s Reaxys and Reaxys Medicinal Chemistry […]

NEW YORK – Schrödinger, a privately held company revolutionizing drug discovery and materials design through advanced molecular simulations, today announced the appointment of veteran biotech leader Rosana Kapeller, M.D., Ph.D., to its board of directors. “I am delighted and honored to join Schrödinger during such a pivotal time in the company’s growth,” said Dr. Kapeller. […]

Scilligence Joins Accenture’s Life Sciences Research Platform Ecosystem to Help Drive Innovation in Drug Discovery and Scientific Research BOSTON: Scilligence, a provider of mobile cheminformatics and bioinformatics for the life sciences industry, has joined the Accenture research platform open partner ecosystem, which will allow for the integration of Scilligence’s informatics solutions. Scilligence’s proprietary technologies address three […]

Stuttgart – Known for providing high-quality chemical information in the field of organic synthesis, Thieme Chemistry has provided approximately 700,000 distinct structures to PubChem – the open chemistry database at the National Institutes of Health (NIH). In addition to the structural information, the upload includes more than 1,200,000 distinct links from chemicals to the Thieme Chemistry […]

Investment in R&D will extend capabilities of computational platform and support growth of partnered and proprietary programs NEW YORK – Schrödinger, a privately held company revolutionizing drug discovery through advanced molecular simulations, today announced the closing of an $85 million financing to support continued growth and innovation of its computational platform and expansion of its […]

DeepMatter, the AIM-listed company focusing on digitizing chemistry, is pleased to announce that it has agreed to acquire from global publisher Springer Nature the entire issued share capital of Infochem GmbH (the “Acquisition” or “Infochem”), a specialist in cheminformatics, for a total consideration of approximately €2.0 million to be satisfied as to €0.36 million in […]

Partnership merges Schrödinger’s advanced modeling capabilities with TB Alliance’s expertise in tuberculosis biology to accelerate the development of next-generation treatments NEW YORK – Dec. 11, 2018 – Schrödinger and TB Alliance today announced a three-year research collaboration to speed the development of next-generation tuberculosis (TB) treatments by leveraging Schrödinger’s advanced computational platform for drug discovery. The […]

Collaboration brings together Schrödinger’s in silico discovery capabilities with SPARC’s novel insights into CNS pathways to speed drug development NEW YORK and MUMBAI, India – Schrödinger and Sun Pharma Advanced Research Company Ltd. (SPARC) (Reuters: SPRC.BO, Bloomberg: SPADV IN, NSE: SPARC, BSE: 532872) today announced a research collaboration to accelerate the discovery of novel CNS therapeutics by leveraging Schrödinger’s […]